Adherence to Oral Chelation in Beta Thalassemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study checks how well children with beta thalassemia stick to their daily oral chelation pill (deferasirox). It aims to find ways to help them take it more regularly, improving iron control and reducing complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with beta thalassemia major or intermedia
- Age between 2 and 18 years old
- Receives regular blood transfusions every 2 to 5 weeks
- Has been taking deferasirox (an oral iron chelation medicine) for at least 1 year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether two common antioxidants—N-acetyl cysteine and alpha lipoic acid—can help people with beta thalassemia. It aims to see if these supplements improve health outcomes when added to usual care.
This trial looks at people with chronic iron overload caused by blood disorders like thalassemia. It tests a medication called deferasirox to see how it affects their quality of life.
This study tests whether motivational interviewing, a type of counseling, helps people with thalassemia take their medications more regularly and feel more confident in managing their health. If you are an adult with thalassemia who needs regular blood transfusions and takes iron chelation therapy, this trial might be for you.
This study looks at how beta-thalassemia (a blood disorder) affects children's teeth and gums. Researchers want to understand oral health challenges in affected children to help improve care.
This trial tests a modified, lower-toxicity preparation (conditioning) before a bone marrow transplant in children and teens with high-risk thalassemia. It aims to reduce treatment side effects while still allowing transplant success for people who need a donor.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.